Pfizer: Hodgkin Disease trials
The registry lists 22 Hodgkin Disease studies with Pfizer as lead sponsor. 0 are open to participants now and 10 have results posted.
Phase 1 14Phase 2 8Phase 3 2No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell LymphomaTerminatedNCT03947255Phase 2Results posted
- Clinical Trial of Brentuximab Vedotin in Classical Hodgkin LymphomaTerminatedNCT03646123Phase 2Results posted
- A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid TumorsTerminatedNCT02663518Phase 1Results posted
- Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS)TerminatedNCT02603419Phase 1Results posted
- A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin LymphomaCompletedNCT02572167Phase 1/2Results posted
- Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin LymphomaCompletedNCT01874054Phase 1/2Results posted
- A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)CompletedNCT01716806Phase 2Results posted
- A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)CompletedNCT01100502Phase 3Results posted
- A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin StudyCompletedNCT00947856Phase 2Results posted
- A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin LymphomaCompletedNCT00848926Phase 2Results posted
- A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced CancersTerminatedNCT06870487Phase 1
- A Safety Study of PF-08046044/SGN-35C in Adults With Advanced CancersTerminatedNCT06254495Phase 1
- A Safety Study of PF-08046045/SGN-35T in Adults With Advanced CancersTerminatedNCT06120504Phase 1
- Safety Study of SEA-CD40 in Cancer PatientsTerminatedNCT02376699Phase 1
- A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001No longer availableNCT01196208
- A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin LymphomaCompletedNCT01060904Phase 1
- Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)CompletedNCT01026415Phase 1
- Cardiac Safety Study of Brentuximab Vedotin (SGN-35)CompletedNCT01026233Phase 1
- A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive MalignanciesTerminatedNCT00649584Phase 1
- Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic MalignanciesCompletedNCT00430846Phase 1
- A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic MalignanciesCompletedNCT00051597Phase 1/2
- Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of ThrombocytopeniaCompletedNCT00039910Phase 3